Cargando…

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease

Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease. Treatment is only effective when received at the early stages of the disease and it involved two drugs (nifurtimox (NF...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolon, Miriam, Hanna, Eustine, Vega, Celeste, Coronel, Cathia, Dea-Ayuela, Maria Auxiliadora, Serrano, Dolores R., Lalatsa, Aikaterini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504116/
https://www.ncbi.nlm.nih.gov/pubmed/36145570
http://dx.doi.org/10.3390/pharmaceutics14091822
_version_ 1784796135082164224
author Rolon, Miriam
Hanna, Eustine
Vega, Celeste
Coronel, Cathia
Dea-Ayuela, Maria Auxiliadora
Serrano, Dolores R.
Lalatsa, Aikaterini
author_facet Rolon, Miriam
Hanna, Eustine
Vega, Celeste
Coronel, Cathia
Dea-Ayuela, Maria Auxiliadora
Serrano, Dolores R.
Lalatsa, Aikaterini
author_sort Rolon, Miriam
collection PubMed
description Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease. Treatment is only effective when received at the early stages of the disease and it involved two drugs (nifurtimox (NFX) and benznidazole (BNZ)). Both treatments require multiple daily administrations of high doses, suffer from variable efficacy and insufficient efficacy in chronic CD, many side effects, and a very long duration of treatment that results in poor compliance, while combined available therapies that lead to reduced duration of treatment are not available and polypharmacy reduces compliance and increases the cost further. Here we present self-nanoemulsified drug delivery systems (SNEDDS) able to produce easily scalable combined formulations of NFX and BNZ that can allow for tailoring of the dose and can be easily converted to oral solid dosage form by impregnation on mesoporous silica particles. SNEDDS demonstrated an enhanced solubilisation capacity for both drugs as demonstrated by flow-through studies and in vitro lipolysis studies. High loading of SNEDDS to Syloid 244 and 3050 silicas (2:1 w/w) allowed clinically translatable amounts of both NFX and BNZ to be loaded. Tablets prepared from NFX-BNZ combined SNEDDS loaded on Syloid 3050 silicas demonstration near complete dissolution in the flow through cell apparatus compared to NFX and BNZ commercial tablets respectively (Lampit(®) and Rochagan(®)). NFX-BNZ-SNEDDS demonstrated nanomolar efficacy in epimastigotes and amastigotes of T. cruzi with acceptable selectivity indexes and demonstrated enhanced survival and reduced parasitaemia in acute murine experimental models of CD. Thus, the results presented here illustrate the ability for an easily scalable and personalised combination oral therapy prepared from GRAS excipients, enabling treatment access worldwide for the treatment of CD.
format Online
Article
Text
id pubmed-9504116
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95041162022-09-24 Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease Rolon, Miriam Hanna, Eustine Vega, Celeste Coronel, Cathia Dea-Ayuela, Maria Auxiliadora Serrano, Dolores R. Lalatsa, Aikaterini Pharmaceutics Article Chagas disease (CD) is a parasitic zoonosis endemic in Central and South America affecting nearly 10 million people, with 100 million people at high risk of contracting the disease. Treatment is only effective when received at the early stages of the disease and it involved two drugs (nifurtimox (NFX) and benznidazole (BNZ)). Both treatments require multiple daily administrations of high doses, suffer from variable efficacy and insufficient efficacy in chronic CD, many side effects, and a very long duration of treatment that results in poor compliance, while combined available therapies that lead to reduced duration of treatment are not available and polypharmacy reduces compliance and increases the cost further. Here we present self-nanoemulsified drug delivery systems (SNEDDS) able to produce easily scalable combined formulations of NFX and BNZ that can allow for tailoring of the dose and can be easily converted to oral solid dosage form by impregnation on mesoporous silica particles. SNEDDS demonstrated an enhanced solubilisation capacity for both drugs as demonstrated by flow-through studies and in vitro lipolysis studies. High loading of SNEDDS to Syloid 244 and 3050 silicas (2:1 w/w) allowed clinically translatable amounts of both NFX and BNZ to be loaded. Tablets prepared from NFX-BNZ combined SNEDDS loaded on Syloid 3050 silicas demonstration near complete dissolution in the flow through cell apparatus compared to NFX and BNZ commercial tablets respectively (Lampit(®) and Rochagan(®)). NFX-BNZ-SNEDDS demonstrated nanomolar efficacy in epimastigotes and amastigotes of T. cruzi with acceptable selectivity indexes and demonstrated enhanced survival and reduced parasitaemia in acute murine experimental models of CD. Thus, the results presented here illustrate the ability for an easily scalable and personalised combination oral therapy prepared from GRAS excipients, enabling treatment access worldwide for the treatment of CD. MDPI 2022-08-29 /pmc/articles/PMC9504116/ /pubmed/36145570 http://dx.doi.org/10.3390/pharmaceutics14091822 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rolon, Miriam
Hanna, Eustine
Vega, Celeste
Coronel, Cathia
Dea-Ayuela, Maria Auxiliadora
Serrano, Dolores R.
Lalatsa, Aikaterini
Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
title Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
title_full Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
title_fullStr Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
title_full_unstemmed Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
title_short Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
title_sort solid nanomedicines of nifurtimox and benznidazole for the oral treatment of chagas disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504116/
https://www.ncbi.nlm.nih.gov/pubmed/36145570
http://dx.doi.org/10.3390/pharmaceutics14091822
work_keys_str_mv AT rolonmiriam solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease
AT hannaeustine solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease
AT vegaceleste solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease
AT coronelcathia solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease
AT deaayuelamariaauxiliadora solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease
AT serranodoloresr solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease
AT lalatsaaikaterini solidnanomedicinesofnifurtimoxandbenznidazolefortheoraltreatmentofchagasdisease